Dyne Therapeutics Inc (US:DYN) — Company Overview, News & Financial Data
Dyne Therapeutics advances muscle disease treatments using its FORCE™ platform, targeting conditions like Duchenne muscular dystrophy.
About Dyne Therapeutics Inc
Dyne Therapeutics (NASDAQ:DYN) focuses on advancing modern muscle disease treatments with cutting-edge scientific discoveries aimed at improving lifecare for patients grappling with serious muscle disorders. Their ambitious projects include developing transformative therapies for conditions such as Duchenne muscular dystrophy, myotonic dystrophy, and facioscapulohumeral muscular dystrophy, employing innovative FORCE™ platform technology to precisely target and deliver therapeutic agents. Dyne's primary objective is to usher in a new era of effective treatments that can significantly enhance the quality of life for those affected by debilitating muscle diseases, demonstrating their commitment to pioneering advances in genetic medicine and therapy delivery.
Snapshot
Operations
Products and/or services of Dyne Therapeutics Inc
- Developing FORCE platform, a proprietary technology aimed at delivering oligonucleotides directly to muscle and heart tissues for treating genetic diseases.
- Advancing DYNE-101, a potential treatment targeting the mutation responsible for myotonic dystrophy type 1 (DM1), designed to improve muscle function.
- Working on DYNE-251 for Duchenne muscular dystrophy (DMD), focusing on skipping exon 51 to restore dystrophin protein production.
- Creating DYNE-301, targeting facioscapulohumeral muscular dystrophy (FSHD), aiming to reduce DUX4 expression, implicated in the disease's progression.
- Progressing with a preclinical program for centronuclear myopathies (CNM), to correct muscle strength and function by targeting underlying genetic mutations.
- Exploring additional therapeutic areas leveraging FORCE platform, extending potential treatments to other genetic muscle and cardiovascular conditions.
Dyne Therapeutics Inc executive team
- Mr. John G. Cox M.B.A.CEO, President & Director
- Dr. Oxana Beskrovnaya Ph.D.Chief Innovation Officer
- Ms. Johanna Friedl-NadererChief Commercial Officer
- Dr. Douglas Kerr M.B.A., M.D., Ph.D.Chief Medical Officer
- Mr. Erick J. Lucera C.F.A., CPACFO, Principal Financial Officer & Principal Accounting Officer and Treasurer
- Dr. Axel WiestSenior VP and Head of Portfolio Strategy & Operations
- Dr. Rajesh Manchanda Ph.D.Chief Technical Officer
- Mr. James P. Bilotta M.B.A.Chief Digital & Information Officer
- Mr. Daniel WilsonSenior VP & Head of Legal
- Ms. Lucia CelonaChief Human Resource Officer